Federal Register Notices

View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.

View Date Published Title Comments Close On Dates
View Prospective Grant of Exclusive License: Monoclonal Antibodies Against Smallpox/Orthopoxviruses Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before February 19, 2010 will be considered.
View Prospective Grant of Exclusive License: Development of V-ATPase Inhibitor Compounds for the Treatment of Human Cancers and Osteoclastic Bone Diseases Excluding Rheumatoid Arthritis and Other Osteo-Specific Auto-Immune Diseases Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 12, 2010 will be considered.
View Prospective Grant of Exclusive License: Diagnostic Tests for Predicting the Emergence of Suicidal Ideation Subsequent to Anti-Depressant Treatment Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 27, 2009 will be considered.
View Government-Owned Inventions; Availability for Licensing
View Government-Owned Inventions; Availability for Licensing
View Prospective Grant of Exclusive License: Methods for Using Extracellular Adenosine Inhibitors and Adenosine Receptor Inhibitors as Applied to the Treatment of Human Cancer and Tumors Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before June 10, 2005 will be considered.
View Prospective Grant of Exclusive License: Use of Hydroxyurea Alone and in Combination with dNTP Competitors for Blocking Reverse Transcriptase Dependent Viruses Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before June 17, 2003 will be considered.